Differences in Clinical Responses to Ustekinumab Treatment among Body Regions: Results from a Real-World Prospective, Observational, and Multi-Center Study in Korea
- Author:
Sang Wook SON
1
;
Dae Young YU
;
Youngdoe KIM
;
Hyo Hyun AHN
;
Yong Hyun JANG
;
Joo Young ROH
;
Young Bok LEE
;
Ji Yeoun LEE
;
Myung Hwa KIM
;
YoungJa LEE
;
Gyeong-Hun PARK
;
Hyun-Sun YOON
;
Sang Woong YOUN
;
Author Information
- Publication Type:Original Article
- From:Annals of Dermatology 2022;34(1):14-21
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:In psoriasis treatment, not all body regions improve simultaneously after clinical interventions.
Objective:This study was aimed at evaluating clinical responses across body regions, which may differentially influence patient treatment plans.
Methods:This prospective, observational, and multi-center study was conducted in Koreans who adhered to ustekinumab treatment based on criteria per local label and reimbursement guidelines. A total of 581 were included in this analysis.
Results:The mean (±standard deviation) psoriasis area severity index (PASI) score at baseline, age, disease duration, and body surface area (%) were 18.9±9.69, 44.2±13.29 years, 11.3±9.65 years, and 27.8±17.83, respectively. Across the head and neck, upper extremities, trunk, and lower extremities, the correlation between the PASI sub-scores for the upper and lower extremities was the highest (r=0.680). The mean PASI sub-score for the lower extremities was the highest at baseline. PASI90 and PASI100 scores were the highest for the head and neck region, indicating the highest response rates, while those for the lower extremities were consistently low at all visits.
Conclusion:We found differences in regional ustekinumab responses, with the lower extremities being the most difficult to treat. These findings should be considered in psoriasis treatment.
